Clinical trials: Active Acne
Wrinkles, Fine Lines
Feasibility Study To Collect Safety And Preliminary Efficacy Data For A Radiofrequency Microneedling Device
The intended use of the Potenza™ device is to collect clinical data for brow lifting and/or treatment of dermatologic conditions in which electrocoagulation and hemostasis is a viable mechanism for means of improvement.
- Conditions
- Wrinkles, Fine Lines, Crepey Skin, Acne Scars
- Trial name
- NCT05254210
- Testing
- RF Device (Potenza™)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Cynosure, Inc.
Acne Vulgaris
To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® Gel
This is an Randomized, Double-blind, Multicentric, Parallel-group, Active and Placebo Controlled, Three Arm Clinical Study. The main objective is to evaluate bioequivalence of Test formulation (Clindamycin Phosphate 1.2%/Benzoyl…
- Trial name
- NCT02005666
- Testing
- Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel, DUAC® Gel
- Where
- 36 sites in United States, India
- Volunteers
- 850 people
- Sponsor
- Zydus Lifesciences Limited
Acne Vulgaris, Acne
A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel
The purpose of this study is to demonstrate the safety and effectiveness of CT Gel in subjects with acne vulgaris. The hypothesis is that CT Gel is superior to Clindamycin Gel, Tretinoin Gel and Vehicle Gel for the treatment of…
- Trial name
- NCT00689117
- Testing
- CT Gel, Clindamycin Gel (clindamycin ), Tretinoin Gel (tretinoin)
- Where
- 32 sites in United States, Belize and 1 more
- Volunteers
- 1,649 people
- Sponsor
- Stiefel, a GSK Company
Acne Vulgaris
Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris
The study hypothesis are based on the assumption that : CD0271 0.3%/CD1579 2.5% Gel provides superior clinical efficacy compared with Topical Gel Vehicle in the overall population and in the subgroup of severe Subjects CD0271…
- Trial name
- NCT01880320
- Testing
- CD0271 0.3% / CD1579 2.5%, CD0271 0.1% / CD1579 2.5%, Topical Gel Vehicle
- Where
- 31 sites in United States, Canada
- Volunteers
- 503 people
- Sponsor
- Galderma R&D
Acne Vulgaris
Anti Propionibacterium(P.) Acnes Activity of Epiduo® Gel Compared to Benzoyl Peroxide (BPO) 2.5% Gel
The purpose of this study is to evaluate the antibacterial activity of Epiduo® Gel (Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel) on P. acnes compared to that of Benzoyl Peroxide 2.5% Gel.
- Trial name
- NCT01188538
- Testing
- Epiduo gel, BPO
- Where
- Poland
- Volunteers
- 40 people
- Sponsor
- Galderma R&D
Acne Vulgaris
Dose Range Study of CD5789 in Acne Vulgaris
To assess the efficacy and safety of different concentrations of CD5789 cream in participants with acne vulgaris for the purpose of dose identification.
- Trial name
- NCT01616654
- Testing
- CD5789 25 µg/g cream, CD5789 50 µg/g cream, CD5789 100 µg/g cream
- Where
- 24 sites in United States
- Volunteers
- 304 people
- Sponsor
- Galderma R&D
Acne Vulgaris
Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne
This is a Randomized, Double-Blind, Controlled Study to evaluate the Safety and Efficacy of a clindamycin / benzoyl peroxide gel in Subjects with Acne Vulgaris
- Trial name
- NCT00776919
- Testing
- clindamycin / benzoyl peroxide gel, clindamycin gel, BPO gel
- Where
- 24 sites in United States, Belize and 1 more
- Volunteers
- 1,315 people
- Sponsor
- Stiefel, a GSK Company
Acne Vulgaris
Clinical Study Between Two Clindamycin 1%/Benzoyl Peroxide 5% Topical Gels
The purpose of this study is to compare the efficacy and safety profiles of Perrigo Israel Pharmaceuticals, Ltd. Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel and Benzaclin® Topical Gel (Clindamycin- Benzoyl Peroxide Gel).
- Trial name
- NCT01138514
- Testing
- Clindamycin 1% / Benzoyl Peroxide 5% (Perrigo), Clindamycin 1% / Benzoyl Peroxide 5% (Benzaclin)
- Volunteers
- 1,555 people
- Sponsor
- Padagis LLC
Hidradenitis Suppurativa
Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa
This is a study to demonstrate the clinical efficacy and safety of the nanobody® sonelokimab administered subcutaneously (sc) compared with placebo in the treatment of adult participants with moderate to severe hidradenitis…
- Trial name
- NCT05322473
- Testing
- Sonelokimab (M1095), Adalimumab
- Where
- 57 sites in United States, Bulgaria and 5 more
- Volunteers
- 234 people
- Sponsor
- MoonLake Immunotherapeutics AG
Acne Vulgaris
Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.
This study is to demonstrate the superiority in efficacy of the GK530G (fixed combination of CD0271 0.1% and CD1579 2.5%) versus each of the monads (CD0271 0.1% and CD1579 2.5%) in the treatment of acne vulgaris for up to 12…
- Trial name
- NCT02073448
- Testing
- GK530G, CD0271, CD1579
- Where
- 13 sites in Japan
- Volunteers
- 417 people
- Sponsor
- Galderma R&D
Acne
A Study to Compare Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% to Acanya® Topical Gel in the Treatment of Acne Vulgaris
The objective of this study was to evaluate the efficacy and safety of Perrigo's test formulation of Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% compared to the already marketed formulation, Acanya gel in…
- Trial name
- NCT01796665
- Testing
- Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5%, Acanya Gel
- Volunteers
- 1,180 people
- Sponsor
- Padagis LLC
Acne Vulgaris
A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris
A study for Subjects with mild to moderate facial acne vulgaris. During the 12-week treatment period subjects randomized to DFD-03 Lotion or Vehicle Lotion will use the study drug twice daily.
- Trial name
- NCT03341910
- Testing
- DFD-03 Lotion, 0.1%, Tazorac Cream, 0.1%, DFD-03 Vehicle Lotion 0%
- Where
- United States
- Volunteers
- 155 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Acne Vulgaris
Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne Vulgaris
This is a randomized, double-blind, multiple-site, placebo-controlled, parallel-group study, designed to compare the efficacy and safety of generic Clindamycin 1% gel (Akorn), and the marketed product Clindamycin 1% gel…
- Trial name
- NCT03522441
- Testing
- Clindamycin 1% Gel
- Where
- 12 sites in United States, Belize
- Volunteers
- 1,125 people
- Sponsor
- Akorn, Inc.
Acne Vulgaris
A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris
A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both Active Treatments to a Vehicle Control in the Treatment of Acne…
- Trial name
- NCT02886715
- Testing
- Tazarotene Cream 0.1%, Tazorac®
- Where
- 25 sites in United States
- Volunteers
- 1,110 people
- Sponsor
- Fougera Pharmaceuticals Inc.
Acne Vulgaris
Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects
This is a multicenter, randomized, single-blinded (investigator's blinded), active-controlled (clindamycin [CLDM] 1% gel), parallel-group study in Japanese subjects with acne vulgaris to demonstrate the efficacy of GSK2585823…
- Trial name
- NCT01445301
- Testing
- GSK2585823(CLDM 1%-BPO 3% gel), CLDM 1% gel twice daily
- Where
- 26 sites in Japan
- Volunteers
- 800 people
- Sponsor
- GlaxoSmithKline